Deborah M Stephens1, Hongli Li1, Michael L LeBlanc1, Soham D Puvvada1, Daniel Persky1, Jonathan W Friedberg1, Sonali M Smith2. 1. Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL. 2. Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL. smsmith@medicine.bsd.uchicago.edu.
Abstract
PURPOSE: Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Subsequent analysis showed an unexpected overlap of the PFS curves. We aimed to confirm and investigate this observation by performing long-term analysis of SWOG S8736 and evaluating these data alongside data from similar patients receiving rituximab and CHOP3RT (SWOG S0014 study). PATIENTS AND METHODS: A subset of patients with limited-stage DLBCL randomly assigned to CHOP8 (n = 150) or CHOP3RT (n = 158) in S8736 was analyzed along with a 56-patient subset treated in S0014 for long-term PFS and OS. RESULTS: Median follow-up in S8736 was 17.7 years. In patients receiving CHOP8 and CHOP3RT, median PFS was 12.0 (95% CI, 8.8 to 14.3) and 11.1 years (95% CI, 8.9 to 14.4), respectively. There were no statistically significant differences in PFS between the groups (P = .73). Median OS was 13.0 (95% CI, 10.4 to 15.2) and 13.7 years (95% CI, 11.1 to 19.4) for patients treated with CHOP8 and CHOP3RT, respectively. Similarly, there were no statistically significant differences in OS between the groups (P = .38). With a median follow-up time 12 years in S0014, 5- and 10-year OS were 82% and 67%, respectively, with a persistent pattern of relapse despite the addition of rituximab. CONCLUSION: Although 5-year PFS and OS were improved after early analysis in patients with limited-stage DLBCL receiving CHOP3RT versus CHOP8, extended survival data showed similar PFS and OS, with continuous treatment failure. The addition of rituximab (S0014) to combined-modality therapy did not mitigate the continued relapse risk, underscoring the value of prolonged clinical trial patient observation and possible unique biology of limited-stage DLBCL.
RCT Entities:
PURPOSE: Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Subsequent analysis showed an unexpected overlap of the PFS curves. We aimed to confirm and investigate this observation by performing long-term analysis of SWOG S8736 and evaluating these data alongside data from similar patients receiving rituximab and CHOP3RT (SWOG S0014 study). PATIENTS AND METHODS: A subset of patients with limited-stage DLBCL randomly assigned to CHOP8 (n = 150) or CHOP3RT (n = 158) in S8736 was analyzed along with a 56-patient subset treated in S0014 for long-term PFS and OS. RESULTS: Median follow-up in S8736 was 17.7 years. In patients receiving CHOP8 and CHOP3RT, median PFS was 12.0 (95% CI, 8.8 to 14.3) and 11.1 years (95% CI, 8.9 to 14.4), respectively. There were no statistically significant differences in PFS between the groups (P = .73). Median OS was 13.0 (95% CI, 10.4 to 15.2) and 13.7 years (95% CI, 11.1 to 19.4) for patients treated with CHOP8 and CHOP3RT, respectively. Similarly, there were no statistically significant differences in OS between the groups (P = .38). With a median follow-up time 12 years in S0014, 5- and 10-year OS were 82% and 67%, respectively, with a persistent pattern of relapse despite the addition of rituximab. CONCLUSION: Although 5-year PFS and OS were improved after early analysis in patients with limited-stage DLBCL receiving CHOP3RT versus CHOP8, extended survival data showed similar PFS and OS, with continuous treatment failure. The addition of rituximab (S0014) to combined-modality therapy did not mitigate the continued relapse risk, underscoring the value of prolonged clinical trial patient observation and possible unique biology of limited-stage DLBCL.
Authors: Julie M Vose; Dennis D Weisenburger; Fausto R Loberiza; Alejandro Arevalo; Martin Bast; Joel Armitage; Philip J Bierman; Robert G Bociek; James O Armitage Journal: Br J Haematol Date: 2010-09-29 Impact factor: 6.998
Authors: Gilles Salles; Daphne de Jong; Wanling Xie; Andreas Rosenwald; Mukesh Chhanabhai; Philippe Gaulard; Wolfram Klapper; Maria Calaminici; Birgitta Sander; Christoph Thorns; Elias Campo; Thierry Molina; Abigail Lee; Michael Pfreundschuh; Sandra Horning; Andrew Lister; Laurie H Sehn; John Raemaekers; Anton Hagenbeek; Randy D Gascoyne; Edie Weller Journal: Blood Date: 2011-05-02 Impact factor: 22.113
Authors: T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: Belinda A Campbell; Joseph M Connors; Randy D Gascoyne; W James Morris; Tom Pickles; Laurie H Sehn Journal: Cancer Date: 2012-01-17 Impact factor: 6.860
Authors: Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Daniel O Persky; Joseph M Unger; Catherine M Spier; Baldassarre Stea; Michael LeBlanc; Matthew J McCarty; Lisa M Rimsza; Richard I Fisher; Thomas P Miller Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick Journal: J Clin Oncol Date: 2004-06-21 Impact factor: 44.544
Authors: Allison Barraclough; Musa Alzahrani; Marianne Schmidt Ettrup; Mark Bishton; Chris van Vliet; Pedro Farinha; Clare Gould; Simone Birch; Laurie H Sehn; Vishakha Sovani; Mitchell Steven Ward; Bradley Augustson; Jorne Biccler; Joseph M Connors; David W Scott; Maher K Gandhi; Kerry J Savage; Tarec El-Galaly; Diego Villa; Chan Yoon Cheah Journal: Blood Adv Date: 2019-07-09
Authors: Yucai Wang; Umar Farooq; Brian K Link; Melissa C Larson; Rebecca L King; Matthew J Maurer; Cristine Allmer; Mehrdad Hefazi; Carrie A Thompson; Ivana N Micallef; Patrick B Johnston; Thomas M Habermann; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Grzegorz S Nowakowski Journal: J Clin Oncol Date: 2019-06-06 Impact factor: 44.544
Authors: Daniel O Persky; Hongli Li; Deborah M Stephens; Steven I Park; Nancy L Bartlett; Lode J Swinnen; Paul M Barr; Jerome D Winegarden; Louis S Constine; Thomas J Fitzgerald; John P Leonard; Brad S Kahl; Michael L LeBlanc; Joo Y Song; Richard I Fisher; Lisa M Rimsza; Sonali M Smith; Thomas P Miller; Jonathan W Friedberg Journal: J Clin Oncol Date: 2020-07-13 Impact factor: 44.544
Authors: Pallawi Torka; Shalin K Kothari; Suchitra Sundaram; Shaoying Li; L Jeffrey Medeiros; Emily C Ayers; Daniel J Landsburg; David A Bond; Kami J Maddocks; Anshu Giri; Brian Hess; Luu Q Pham; Ranjana Advani; Yang Liu; Stefan Klaus Barta; Julie M Vose; Michael C Churnetski; Jonathon B Cohen; Madelyn Burkart; Reem Karmali; Joanna Zurko; Amitkumar Mehta; Adam J Olszewski; Sarah Lee; Brian T Hill; Timothy F Burns; Frederick Lansigan; Emma Rabinovich; David Peace; Adrienne Groman; Kristopher Attwood; Francisco J Hernandez-Ilizaliturri Journal: Blood Adv Date: 2020-01-28